WO2008108729A1 - Novel 2-heteroaryl substituted indoles 695 - Google Patents
Novel 2-heteroaryl substituted indoles 695 Download PDFInfo
- Publication number
- WO2008108729A1 WO2008108729A1 PCT/SE2008/050242 SE2008050242W WO2008108729A1 WO 2008108729 A1 WO2008108729 A1 WO 2008108729A1 SE 2008050242 W SE2008050242 W SE 2008050242W WO 2008108729 A1 WO2008108729 A1 WO 2008108729A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound according
- fluoroalkyl
- methoxy
- methyl
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 254
- 238000000034 method Methods 0.000 claims abstract description 64
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 31
- 239000002243 precursor Chemical class 0.000 claims abstract description 30
- 208000037259 Amyloid Plaque Diseases 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 238000003384 imaging method Methods 0.000 claims abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 238000001727 in vivo Methods 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 11
- -1 hydroxy, methoxy Chemical group 0.000 claims description 123
- 125000000217 alkyl group Chemical group 0.000 claims description 103
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 86
- 125000004429 atom Chemical group 0.000 claims description 41
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 37
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 28
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 25
- 230000027455 binding Effects 0.000 claims description 22
- 125000001153 fluoro group Chemical group F* 0.000 claims description 22
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000002947 alkylene group Chemical group 0.000 claims description 17
- 125000001246 bromo group Chemical group Br* 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 125000002346 iodo group Chemical group I* 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 238000011503 in vivo imaging Methods 0.000 claims description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 11
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000000565 sulfonamide group Chemical group 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 201000010374 Down Syndrome Diseases 0.000 claims description 8
- 206010044688 Trisomy 21 Diseases 0.000 claims description 8
- 125000004414 alkyl thio group Chemical group 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 8
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 108700028369 Alleles Proteins 0.000 claims description 7
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 238000004611 spectroscopical analysis Methods 0.000 claims description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 7
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims description 6
- 208000015756 familial Alzheimer disease Diseases 0.000 claims description 6
- 239000012458 free base Substances 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- AMSTWUVZBSJAPO-UHFFFAOYSA-N 5-(1h-indol-2-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC=C1C1=CC2=CC=CC=C2N1 AMSTWUVZBSJAPO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- XSXHWVKGUXMUQE-UHFFFAOYSA-N osmium dioxide Inorganic materials O=[Os]=O XSXHWVKGUXMUQE-UHFFFAOYSA-N 0.000 claims description 4
- KLPQADIFPSBTPY-UHFFFAOYSA-N tert-butyl 5-methoxy-2-[6-(methylamino)pyridin-3-yl]indole-1-carboxylate Chemical compound C1=NC(NC)=CC=C1C1=CC2=CC(OC)=CC=C2N1C(=O)OC(C)(C)C KLPQADIFPSBTPY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- MNCMBBIFTVWHIP-UHFFFAOYSA-N 1-anthracen-9-yl-2,2,2-trifluoroethanone Chemical group C1=CC=C2C(C(=O)C(F)(F)F)=C(C=CC=C3)C3=CC2=C1 MNCMBBIFTVWHIP-UHFFFAOYSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 claims description 3
- 239000000470 constituent Substances 0.000 claims description 3
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 238000002595 magnetic resonance imaging Methods 0.000 claims description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 29
- 210000004556 brain Anatomy 0.000 abstract description 22
- 229940054051 antipsychotic indole derivative Drugs 0.000 abstract description 11
- 229940124597 therapeutic agent Drugs 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 125000003118 aryl group Chemical group 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 18
- 125000006239 protecting group Chemical group 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 16
- 238000002372 labelling Methods 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 13
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 12
- 239000007832 Na2SO4 Substances 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 230000009466 transformation Effects 0.000 description 12
- 238000005804 alkylation reaction Methods 0.000 description 11
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 10
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 238000002600 positron emission tomography Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 230000029936 alkylation Effects 0.000 description 8
- 206010002022 amyloidosis Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000002603 single-photon emission computed tomography Methods 0.000 description 8
- 238000000844 transformation Methods 0.000 description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
- 230000000269 nucleophilic effect Effects 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 239000002287 radioligand Substances 0.000 description 7
- 229910052722 tritium Inorganic materials 0.000 description 7
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 206010016202 Familial Amyloidosis Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 6
- 125000005466 alkylenyl group Chemical group 0.000 description 6
- 230000003941 amyloidogenesis Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000000159 protein binding assay Methods 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- BKYRONJOTOZEGB-UHFFFAOYSA-N 5-(5-methoxy-1h-indol-2-yl)-n-methylpyridin-2-amine Chemical compound C1=NC(NC)=CC=C1C1=CC2=CC(OC)=CC=C2N1 BKYRONJOTOZEGB-UHFFFAOYSA-N 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- KACZDVQUYFTKFL-UHFFFAOYSA-N methyl 6-(5-methoxy-1h-indol-2-yl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CC2=CC(OC)=CC=C2N1 KACZDVQUYFTKFL-UHFFFAOYSA-N 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- VNLDZPGDHVKUHH-UHFFFAOYSA-N 5-(5-fluoro-1h-indol-2-yl)-n-methylpyridin-2-amine Chemical compound C1=NC(NC)=CC=C1C1=CC2=CC(F)=CC=C2N1 VNLDZPGDHVKUHH-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000012216 imaging agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052763 palladium Inorganic materials 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- PQQYTZOQBOERJZ-UHFFFAOYSA-N 2-[6-(methylamino)pyridin-3-yl]-1h-indol-5-ol Chemical compound C1=NC(NC)=CC=C1C1=CC2=CC(O)=CC=C2N1 PQQYTZOQBOERJZ-UHFFFAOYSA-N 0.000 description 3
- SZCASYJKGSDWRF-UHFFFAOYSA-N 5-(5-fluoro-1h-indol-2-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(=O)N)=CC=C1C1=CC2=CC(F)=CC=C2N1 SZCASYJKGSDWRF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- 235000010724 Wisteria floribunda Nutrition 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 125000004849 alkoxymethyl group Chemical group 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000017105 hereditary amyloidosis Diseases 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000009206 nuclear medicine Methods 0.000 description 3
- 239000012038 nucleophile Substances 0.000 description 3
- 238000007339 nucleophilic aromatic substitution reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- SDHHYFPFMMHZBX-UHFFFAOYSA-N tert-butyl 2-(6-carbamoylpyridin-3-yl)-5-fluoroindole-1-carboxylate Chemical compound C=1C2=CC(F)=CC=C2N(C(=O)OC(C)(C)C)C=1C1=CC=C(C(N)=O)N=C1 SDHHYFPFMMHZBX-UHFFFAOYSA-N 0.000 description 3
- AUIXMWKVLPXKGC-UHFFFAOYSA-N (5-bromopyridin-2-yl)methanamine Chemical compound NCC1=CC=C(Br)C=N1 AUIXMWKVLPXKGC-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- IPWPEOLXILHOLV-UHFFFAOYSA-N 5-bromopyridine-2-carboxamide Chemical compound NC(=O)C1=CC=C(Br)C=N1 IPWPEOLXILHOLV-UHFFFAOYSA-N 0.000 description 2
- 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229910015845 BBr3 Inorganic materials 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- KWSGEMFREWGVGJ-UHFFFAOYSA-N CC(Nc1ncc(-c2cc3cc(CN(C)c4ccc(-c5cc6ccccc6[nH]5)nc4)ccc3[nH]2)nc1)=O Chemical compound CC(Nc1ncc(-c2cc3cc(CN(C)c4ccc(-c5cc6ccccc6[nH]5)nc4)ccc3[nH]2)nc1)=O KWSGEMFREWGVGJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 238000010934 O-alkylation reaction Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000006619 Stille reaction Methods 0.000 description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 238000006555 catalytic reaction Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000026030 halogenation Effects 0.000 description 2
- 238000005658 halogenation reaction Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- CLXVQMSNBCCFDS-UHFFFAOYSA-N methyl 6-(5-hydroxy-1h-indol-2-yl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CC2=CC(O)=CC=C2N1 CLXVQMSNBCCFDS-UHFFFAOYSA-N 0.000 description 2
- 238000002610 neuroimaging Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- 208000022256 primary systemic amyloidosis Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000002577 pseudohalo group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- JPRSQMOZXPEEME-UHFFFAOYSA-N tert-butyl 2-(6-carbamoylpyridin-3-yl)indole-1-carboxylate Chemical compound C=1C2=CC=CC=C2N(C(=O)OC(C)(C)C)C=1C1=CC=C(C(N)=O)N=C1 JPRSQMOZXPEEME-UHFFFAOYSA-N 0.000 description 2
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 0 *NC(c(nc1)ccc1-c1cc2cc(F)ccc2[n]1)O Chemical compound *NC(c(nc1)ccc1-c1cc2cc(F)ccc2[n]1)O 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- WJUKOGPNGRUXMG-UHFFFAOYSA-N 1,2-dibromo-1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)(Br)C(Cl)(Cl)Br WJUKOGPNGRUXMG-UHFFFAOYSA-N 0.000 description 1
- GBBZLMLLFVFKJM-UHFFFAOYSA-N 1,2-diiodoethane Chemical compound ICCI GBBZLMLLFVFKJM-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 150000005749 2-halopyridines Chemical class 0.000 description 1
- ZPIHHIRJUPXETJ-UHFFFAOYSA-N 2-iodo-1h-indole Chemical compound C1=CC=C2NC(I)=CC2=C1 ZPIHHIRJUPXETJ-UHFFFAOYSA-N 0.000 description 1
- RGDQRXPEZUNWHX-UHFFFAOYSA-N 3-methylpyridin-2-amine Chemical compound CC1=CC=CN=C1N RGDQRXPEZUNWHX-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- RLFJQNWCNZVFSV-UHFFFAOYSA-N 5-(1h-indol-2-yl)-n-methylpyridin-2-amine Chemical compound C1=NC(NC)=CC=C1C1=CC2=CC=CC=C2N1 RLFJQNWCNZVFSV-UHFFFAOYSA-N 0.000 description 1
- HXXPTRDMSQJHDN-UHFFFAOYSA-N 5-methoxy-2-(5-methoxycarbonylpyridin-2-yl)indole-1-carboxylic acid Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CC2=CC(OC)=CC=C2N1C(O)=O HXXPTRDMSQJHDN-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000023769 AA amyloidosis Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000006998 Katritzky reaction Methods 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 206010039811 Secondary amyloidosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003942 amyloidogenic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 238000006795 borylation reaction Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005388 cross polarization Methods 0.000 description 1
- 238000007333 cyanation reaction Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- JCWIWBWXCVGEAN-UHFFFAOYSA-L cyclopentyl(diphenyl)phosphane;dichloropalladium;iron Chemical compound [Fe].Cl[Pd]Cl.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1.[CH]1[CH][CH][CH][C]1P(C=1C=CC=CC=1)C1=CC=CC=C1 JCWIWBWXCVGEAN-UHFFFAOYSA-L 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical compound B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- UZZWBUYVTBPQIV-UHFFFAOYSA-N dme dimethoxyethane Chemical compound COCCOC.COCCOC UZZWBUYVTBPQIV-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000007345 electrophilic aromatic substitution reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- OLAMWIPURJGSKE-UHFFFAOYSA-N et2o diethylether Chemical compound CCOCC.CCOCC OLAMWIPURJGSKE-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- INQOMBQAUSQDDS-NJFSPNSNSA-N iodomethane Chemical compound I[14CH3] INQOMBQAUSQDDS-NJFSPNSNSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000000622 liquid--liquid extraction Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003923 mental ability Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- JZPPQYIDUVDPJN-UHFFFAOYSA-N methyl 6-(5-hydroxy-1h-indol-2-yl)pyridine-3-carboxylate;methyl 6-(5-methoxy-1h-indol-2-yl)pyridine-3-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CC2=CC(O)=CC=C2N1.N1=CC(C(=O)OC)=CC=C1C1=CC2=CC(OC)=CC=C2N1 JZPPQYIDUVDPJN-UHFFFAOYSA-N 0.000 description 1
- NFLROFLPSNZIAH-UHFFFAOYSA-N methyl 6-bromopyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Br)N=C1 NFLROFLPSNZIAH-UHFFFAOYSA-N 0.000 description 1
- OIRDBPQYVWXNSJ-UHFFFAOYSA-N methyl trifluoromethansulfonate Chemical compound COS(=O)(=O)C(F)(F)F OIRDBPQYVWXNSJ-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000956 solid--liquid extraction Methods 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 229940056501 technetium 99m Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- IMNAWIZARVLHAD-UHFFFAOYSA-N tert-butyl 5-fluoro-2-[6-(methylamino)pyridin-3-yl]indole-1-carboxylate Chemical compound C1=NC(NC)=CC=C1C1=CC2=CC(F)=CC=C2N1C(=O)OC(C)(C)C IMNAWIZARVLHAD-UHFFFAOYSA-N 0.000 description 1
- PWULHKKHESMSNN-UHFFFAOYSA-N tert-butyl 5-methoxy-2-(5-methoxycarbonylpyridin-2-yl)indole-1-carboxylate Chemical compound N1=CC(C(=O)OC)=CC=C1C1=CC2=CC(OC)=CC=C2N1C(=O)OC(C)(C)C PWULHKKHESMSNN-UHFFFAOYSA-N 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005309 thioalkoxy group Chemical group 0.000 description 1
- JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PIILXFBHQILWPS-UHFFFAOYSA-N tributyltin Chemical compound CCCC[Sn](CCCC)CCCC PIILXFBHQILWPS-UHFFFAOYSA-N 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 150000008648 triflates Chemical class 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- LYRCQNDYYRPFMF-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C LYRCQNDYYRPFMF-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to novel 2-heteroaryl substituted indole derivatives and therapeutic uses for such compounds. Furthermore, the invention relates to novel 2- heteroaryl substituted indole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measureing clinical efficacy of Alzheimer's disease therapeutic agents.
- Amyloidosis is a progressive, incurable metabolic disease of unknown cause characterized by abnormal deposits of protein in one or more organs or body systems. Amyloid proteins are manufactured, for example, by malfunctioning bone marrow. Amyloidosis, which occurs when accumulated amyloid deposits impair normal body function, can cause organ failure or death. It is a rare disease, occurring in about eight of every 1,000,000 people. It affects males and females equally and usually develops after the age of 40. At least 15 types of amyloidosis have been identified. Each one is associated with deposits of a different kind of protein.
- amyloidosis The major forms of amyloidosis are primary systemic, secondary, and familial or hereditary amyloidosis. There is also another form of amyloidosis associated with Alzheimer's disease. Primary systemic amyloidosis usually develops between the ages of 50 and 60. With about 2,000 new cases diagnosed annually, primary systemic amyloidosis is the most common form of this disease in the United States. Also known as light-chain- related amyloidosis, it may also occur in association with multiple myeloma (bone marrow cancer). Secondary amyloidosis is a result of chronic infection or inflammatory disease.
- Familial Mediterranean fever a bacterial infection characterized by chills, weakness, headache, and recurring fever
- Granulomatous ileitis inflammation of the small intestine
- Hodgkin's disease Leprosy, Osteomyelitis and Rheumatoid arthritis.
- Familial or hereditary amyloidosis is the only inherited form of the disease. It occurs in members of most ethnic groups, and each family has a distinctive pattern of symptoms and organ involvement. Hereditary amyloidosis is though to be autosomal dominant, which means that only one copy of the defective gene is necessary to cause the disease. A child of a parent with familial amyloidosis has a 50-50 risk of developing the disease.
- Amyloidosis can involve any organ or system in the body. The heart, kidneys, gastrointestinal system, and nervous system are affected most often. Other common sites of amyloid accumulation include the brain, joints, liver, spleen, pancreas, respiratory system, and skin.
- AD Alzheimer's disease
- AD is the most common form of dementia, a neurologic disease characterized by loss of mental ability severe enough to interfere with normal activities of daily living, lasting at least six months, and not present from birth. AD usually occurs in old age, and is marked by a decline in cognitive functions such as remembering, reasoning, and planning.
- AD Alzheimer's disease
- amyloid A ⁇ -peptide in the brain is a pathological hallmark of all forms of AD. It is generally accepted that deposition of cerebral amyloid A ⁇ -peptide is the primary influence driving AD pathogenesis. (Hardy J and Selkoe DJ. , Science. 297: 353- 356, 2002).
- Imaging techniques such as positron emission tomography (PET) and single photon emission computed tomography (SPECT), are effective in monitoring the accumulation of amyloid deposits in the brain and correlating it to the progression of AD (Shoghi-Jadid et al. The American journal of geriatric psychiatry 2002, 10, 24; Miller, Science, 2006, 313, 1376; Coimbra et al. Curr. Top. Med. Chem. 2006, 6, 629; Nordberg, Lancet Neurol. 2004, 3, 519).
- PET positron emission tomography
- SPECT single photon emission computed tomography
- amyloid binding compounds that can cross the blood-brain barrier, and consequently, can be used in diagnostics. Furthermore, it is important to be able to monitor the efficacy of the treatment given to AD patients, by measuring the effect of said treatment by measuring changes of AD plaque level.
- Indole derivatives have previously been described for use in association with an amyloidogenic peptide (WO 1995017095), and some indole derivatives have previously been described for use as amyloid imaging agents (WO04083195, WO2002085903).
- amyloid imaging agents WO04083195, WO2002085903.
- the present invention provides novel 2-heteroaryl substituted indole derivatives for use as amyloid imaging agents and treatment of amyloid related diseases. Disclosure of the invention
- Rl is selected from H, halo, methyl, Ci -5 fluoroalkyl, Ci -3 alkyleneOCi- 3 alkyl, Ci -3 alkyleneOCi.3 fluorolkyl, Ci -3 alkyleneNH 2 , Ci -3 alkyleneNHCi -3 alkyl, Ci -3 alky leneN(C i -3 alkyl) 2 , Ci -3 alkyleneNHCi -3 fluoroalkyl, Ci -3 alkyleneN(Ci -3 fluoroalkyl) 2 , Ci -3 alky leneN(C i -3 alkyl)Ci -3 fluoroalkyl, hydroxy, methoxy, Ci -5 fluoroalkoxy, Ci -5 alkylthio, Ci -5 fluoroalkylthio, amino, NHCi -3 alkyl, NHCi -3 fluoroalkyl, N(Ci -3 alkyl) 2 , N(Ci -3 alkyl)C
- R2 is selected from H, halo, methyl, Ci -5 fluoroalkyl, Ci -3 alkyleneOCi -3 alkyl, Ci -3 alkyleneOCi -3 fluorolkyl, Ci -3 alkyleneNH 2 , Ci -3 alkyleneNHCi -3 alkyl, Ci -3 alky leneN(C i -3 alkyl) 2 , Ci -3 alkyleneNHCi -3 fluoroalkyl, Ci -3 alkyleneN(Ci -3 fluoroalkyl) 2 , Ci -3 alky leneN(C i -3 alkyl)Ci -3 fluoroalkyl, hydroxy, methoxy, Ci -5 fluoroalkoxy, Ci -5 alkylthio, Ci -5 fluoroalkylthio, amino, NHCi -3 alkyl, NHCi -3 fluoroalkyl, N(Ci -3 alkyl) 2 , N(Ci -3 alkyl)C
- Q is a nitrogen-containing aromatic heterocycle selected from Q2 to QlO;
- Q2 is a 6-membered aromatic heterocycle containing one or two N atoms, wherein Xi, X 2 , X 3 and X 4 are independently selected from N or C; and wherein one or two of Xi, X 2 , X 3 and X 4 is N and the remaining is C and when said Xi is C, said C is optionally substituted with R4; and when said X 2 is C, said C is optionally substituted with R5;
- R3 is selected from methoxy, Ci -4 fluoroalkoxy, amino, NHCi -3 alkyl, NHCi -3 fluoroalkyl, N(Ci -3 alkyl) 2 , N(Ci -3 alkyl)Ci -3 fluoroalkyl, NH(CO)Ci -3 alkyl, NH(CO)Ci -3 fluoroalkyl, NH(C0)G2, (CO)NH 2 , (CO)Ci -3 alkoxy, methylthio, Ci -6 fluoroalkylthio, SO 2 NH 2 , N(C 4-6 alkylene) and Gl;
- X 5 is selected from O, NH, NCi -3 alkyl and N(CO)Ot-butyl;
- G2 is phenyl, optionally substituted with a substituent selected from fluoro and iodo;
- R4 is selected from H and halo
- R5 is selected from H, fluoro, bromo and iodo
- R6 is selected from H, methyl and (CH 2 ) O-4 CH 2 F;
- R7 is selected from H, methyl, (CO)Ci -4 alkoxy and (CH 2 )O -4 CH 2 F;
- one or more of the constituting atoms optionally is a detectable isotope; as a free base or a pharmaceutically acceptable salt, solvate or solvate of a salt thereof; with the provisio that the following compounds are excluded:
- Rl is selected from H, halo, methyl, Ci -5 fluoroalkyl, hydroxy, methoxy, Ci -5 fluoroalkoxy, methylthio, Ci -5 fluoroalkylthio, amino, NHmethyl, NHCi -3 fluoroalkyl, N(CH 3 )CH 3 , N(Ci -3 alkyl)Ci -3 fluoroalkyl, NH(CO)Ci -3 alkyl, NH(CO)Ci -3 fluoroalkyl, NH(CO)Ci -3 alkoxy, NH(CO)Ci -3 fluoroalkoxy, NHSO 2 Ci -3 alkyl, NHSO 2 Ci -3 fluoroalkyl, (CO)Ci -3 fluoroalkyl, (CO)Ci -3 alkoxy, (CO)Ci -3 fluoroalkoxy, (CO)NH 2 ,
- Rl is selected from H, fluoro, iodo, methyl, Ci -S fluoroalkyl, hydroxy, methoxy, cyano, Ci -5 fluoroalkoxy, methylthio, amino, NHmethyl, NHCi -3 fluoroalkyl, NH(CO)Ci -3 alkyl, NH(CO)Ci -3 fluoroalkyl, NH(CO)Ci -3 fluoroalkoxy, (CO)Ci -3 alkoxy and (CO)NH 2 .
- R2 is selected from H, fluoro, iodo, Ci -5 fluoroalkyl, hydroxy, methoxy, (CO)NH 2 , cyano and methylthio.
- a compound according to formula Ia wherein Q is selected from Q3 to QlO.
- Q2 is a pyridine ring, wherein X 3 and X 4 are independently selected from N or C, and wherein one of X 3 and X 4 is N and the remaining of Xi, X 2 , X 3 and X 4 are C. 5
- a compound according to formula Ia wherein Q2 is a pyridazine ring, wherein X 3 and X 4 are N, and wherein Xi and X 2 are C. 5
- a compound according to formula Ia wherein Q2 is a pyrazine ring, wherein Xi and X 4 are N, and wherein X 2 and X 3 are C; or wherein Xi and X4 are C, and wherein X 2 and X 3 are N.
- a compound according to formula Ia,o wherein R3 is selected from methoxy, C 1-4 fluoroalkoxy, amino, NHCi -3 alkyl, NHCi -3 fluoroalkyl, N(Ci -3 alkyl) 2 , N(Ci -3 alkyl)Ci_ 3 fluoroalkyl, NH(CO)Ci -3 alkyl, NH(CO)Ci -3 fluoroalkyl, (CO)NH 2 , (CO)Ci -3 alkoxy, methylthio, Ci -6 fluoroalkylthio, SO 2 NH 2 , and Gl; wherein X 5 is selected from O, NH and Nmethyl. 5
- R3 is selected from NHmethyl, (CO)NH 2 , (CO)methoxy.
- R5 is selected from H and fiuoro.
- a compound wherein one to six of the composing atoms is the detectable isotope 3 H, or wherein one to three of the composing atoms is the detectable isotope 13 C, or wherein one of the composing atoms is a detectable isotope selected from 18 F, 11 C, 75 Br, 76 Br, 120 1, 123 1, 125 1, 131 I and 14 C, said compound being selected from:
- a compound according to formula Ia wherein one to six of the composing atoms is the detectable isotope 3 H, or wherein one to three of the composing atoms is a detectable isotope selected from 19 F and 13 C, or wherein one of the composing atoms is a detectable isotope selected from 18 F, 11 C, 75 Br, 76 Br, 120 I, 123 I, 125 1, 131 I and 14 C.
- a compound according to formula Ia wherein one to six of the composing atoms is the detectable isotope 3 H, or wherein one to three of the composing atoms is the detectable isotope 19 F, or wherein one of the composing atoms is a detectable isotope selected from 18 F, 11 C and 123 I.
- a compound according to formula Ia wherein one to six of the composing atoms is the detectable isotope 3 H, or wherein one to three of the composing atoms is the detectable isotope 19 F, or wherein one of the composing atoms is a detectable isotope selected from 18 F and 11 C.
- Z is a 6-membered aromatic heterocycle containing one or two N atoms, wherein X 6 , X 7 and Xs are independently selected from N or C, and wherein one or two OfX 6 , X 7 and Xs is N and the remaining is C, and wherein X 6 is C, said C is optionally substituted with R9;
- R8 is selected from OSi(G3) 3 , OCH 2 G4, OG5, H, bromo, f ⁇ ioro, hydroxy, methoxy, Sn(Q- 4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + and nitro;
- R9 is selected from H, bromo, fiuoro, Sn(Ci -4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + and nitro;
- RlO is selected from amino, methylamino, dimethylamino, methoxy, hydroxy, (CO)NH 2 , O(CH 2 ) 2-4 G7 and NH(CH 2 ) 2-4 G7;
- Rl 1 is selected from OSi(G3)3, OCH 2 G4, OG5, H, bromo, fluoro, hydroxy, methoxy, Sn(Ci -4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + and nitro;
- G3 is selected from Ci -4 alkyl and phenyl
- G4 is selected from 2-(trimethylsilyl)ethoxy, Ci -3 alkoxy, 2-(Ci -3 alkoxy)ethoxy, Ci -3 alkylthio, cyclopropyl, vinyl, phenyl, /?-methoxyphenyl, ⁇ -nitrophenyl, and 9-anthryl;5
- G5 is selected from tetrahydropyranyl, 1-ethoxyethyl, phenacyl, 4-bromophenacyl, cyclohexyl, t-butyl, t-butoxycarbonyl, 2,2,2-trichloroethylcarbonyl and triphenylmethyl;
- IG6 + represents a constituent of a iodonium salt, in which the iodo atom is hyper- valento and has a positive formal charge and, in which G6 is phenyl, optionally substituted with one substituent selected from methyl and bromo;
- G7 is selected from bromo, iodo, OSO 2 CF 3 , OSO 2 CH 3 and 0S0 2 phenyl, said phenyl being optionally substituted with methyl or bromo; 5
- Rl 2 is H; (2) one or several of the substituents selected from R8, R9, RlO, Rl 1 is one of the functional groups selected from bromo, fluoro, hydroxy, Sn(Ci -4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + , nitro, amino, methylamino, NH(CH 2 ) 2-4 G7, O(CH 2 ) 2-4 G7 and (CH 2 ) 2-4 G7; o as a free base or a salt, solvate or solvate of a salt thereof; with the provisio following compounds are excluded:
- Z is a 6-membered aromatic heterocycle containing one or two N atoms, wherein X 6 , X 7 and Xs are independently selected from N or C, and wherein one or two OfX 6 , X 7 and Xs is N and the remaining is C, and wherein X 6 is C, said C is optionally substituted with R9, and wherein X 7 is C, said C is optionally substituted with R9, and wherein Xs is C, said C is optionally substituted with R9;
- R8 is selected from OSi(G3)3, OCH2G4, OG5, H, bromo, fluoro, hydroxy, methoxy, Sn(C 1- 4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + and nitro;
- R9 is selected from H, bromo, chloro, iodo, fluoro, Sn(Ci -4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + and nitro;
- RlO is selected from amino, methylamino, dimethylamino, N(CH 3 )CHO, N(CH 3 )COCH 3 , N(CH 3 )CO 2 -t-butyl, methoxy, hydroxy, (CO)NH 2 , O(CH 2 ) 2-4 G7 and NH(CH 2 ) 2-4 G7;
- Rl 1 is selected from OSi(G3) 3 , OCH 2 G4, 0G5, H, bromo, fluoro, hydroxy, methoxy, Sn(Ci -4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + and nitro;
- G3 is selected from Ci -4 alkyl and phenyl
- G4 is selected from 2-(trimethylsilyl)ethoxy, Ci -3 alkoxy, 2-(Ci -3 alkoxy)ethoxy, Ci -3 alkylthio, cyclopropyl, vinyl, phenyl, /?-methoxyphenyl, ⁇ -nitrophenyl, and 9-anthryl;
- G5 is selected from tetrahydropyranyl, 1-ethoxyethyl, phenacyl, 4-bromophenacyl, cyclohexyl, t-butyl, t-butoxycarbonyl, 2,2,2-trichloroethylcarbonyl and triphenylmethyl;
- IG6 + represents a constituent of a iodonium salt, in which the iodo atom is hyper- valent and has a positive formal charge and, in which G6 is phenyl, optionally substituted with one substituent selected from methyl and bromo;
- G7 is selected from bromo, iodo, OSO 2 CF 3 , OSO 2 CH 3 and 0S0 2 phenyl, said phenyl being optionally substituted with methyl or bromo;
- Rl 2 is H; (2) one or several of the substituents selected from R8, R9, RlO, Rl 1 is one of the functional groups selected from bromo, fluoro, hydroxy, Sn(Ci -4 alkyl) 3 , N(CH 3 ) 3 + , IG6 + , N 2 + , nitro, amino, methylamino, NH(CH 2 ) 2-4 G7, N(CH 3 )CHO, N(CH 3 )COCH 3 , N(CH 3 )CO 2 -t-butyl, O(CH 2 ) 2-4 G7, OSi(G3) 3 , OCH 2 G4 and (CH 2 ) 2-4 G7; as a free base or a salt, solvate or solvate of a salt thereof;
- R8 is H
- RlO is selected from amino, methylamino, dimethylamino and NH(CH 2 ) 2-4 G7
- Rl 1 is selected from OSi(CH 3 ) 2 C(CH 3 ) 3 , H, f ⁇ ioro, hydroxy, methoxy, Sn(Ci_4 alkyl) 3 and N 2 +
- RI l is selected from OSi(CH 3 ) 2 C(CH 3 ) 3 , H, fiuoro, hydroxy, methoxy, OCH 2 G4, Sn(Ci -4 alkyl) 3 and N 2 + ;
- a compound according to formula Ib wherein Z is a pyridine ring, wherein X 6 and Xs are C, and wherein X 7 is N.
- Z is a pyrimidine ring, wherein X 6 and Xs are N, and wherein X 7 is C.
- a pharmaceutical composition comprising a compound according to formula Ia, together with a pharmaceutically acceptable carrier.
- a pharmaceutical composition for in vivo imaging of amyloid deposits comprising a radio-labeled compound according to formula Ia, together with a pharmaceutically acceptable carrier.
- an in vivo method for measuring amyloid deposits in a subject comprising the steps of: (a) administering a detectable quantity of a pharmaceutical composition for in vivo imaging of amyloid deposits, comprising a radio-labeled compound according to formula Ia, together with a pharmaceutically acceptable carrier, and (b): detecting the binding of the compound to amyloid deposit in the subject.
- said detection is carried out by the group of techniques selected from gamma imaging, magnetic resonance imaging and magnetic resonance spectroscopy.
- said subject is suspected of having a disease or syndrome selected from the group consisting of Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
- a compound of formula Ia in the manufacture of a medicament for prevention and/or treatment of Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.
- a method of prevention and/or treatment of Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele comprising administrering to a mammal, including man in need of such prevention and/or treatment, a therapeutically effective amount of a compound of formula Ia.
- alkyl As used herein, “alkyl”, “alkylenyl” or “alkylene” used alone or as a suffix or prefix, is intended to include both branched and straight chain saturated aliphatic hydrocarbon groups having from 1 to 12 carbon atoms or if a specified number of carbon atoms is provided then that specific number would be intended.
- C 1-6 alkyl denotes alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.
- a hydrogen-atom is intended as the substituent at the position of the alkyl-group.
- N(Co alkyl) 2 is equivalent to "NH 2 " (amino).
- a bond is intended to link the groups onto which the alkylenyl or alkylene-group is substituted.
- “NH(Co alkylene)NH2” is equivalent to "NHNH 2 " (hydrazino).
- the groups linked by an alkylene or alkylenyl-group are intended to be attached to the first and to the last carbon of the alkylene or alkylenyl-group. In the case of methylene, the first and the last carbon is the same. For example, "N(C 4 alkylene)", “N(C 5 alkylene)" and
- N(C 2 alkylene) 2 NH is equivalent to pyrrolidinyl, piperidinyl and piperazinyl, repectively.
- alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, pentyl, and hexyl.
- alkylene or alkylenyl examples include, but are not limited to, methylene, ethylene, propylene, and butylene.
- alkoxy or "alkyloxy” represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
- alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, t-butoxy, n-pentoxy, isopentoxy, cyclopropylmethoxy, allyloxy and propargyloxy.
- alkylthio or “thioalkoxy” represent an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge.
- fluoroalkyl refers to groups in which one, two, or three of the hydrogen(s) attached to the carbon(s) of the corresponding alkyl, alkylene and alkoxy-groups are replaced by fluoro.
- fluoroalkyl include, but are not limited to, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 2-fluoroethyl and 3-fluoropropyl.
- fluoroalkylene include, but are not limited to, difluoromethylene, fluoromethylene, 2,2-difluorobutylene and 2,2,3-trifluorobutylene.
- fluoroalkoxy examples include, but are not limited to, trifluoromethoxy, 2,2,2- trifluoroethoxy, 3,3,3-trifluoropropoxy and 2,2-difluoropropoxy.
- aromatic refers to hydrocarbonyl groups having one or more unsaturated carbon ring(s) having aromatic characters, (e.g. 4n + 2 delocalized electrons where "n” is an integer) and comprising up to about 14 carbon atoms.
- heteromatic refers to groups having one or more unsaturated rings containing carbon and one or more heteroatoms such as nitrogen, oxygen or sulphur having aromatic character (e.g. 4n + 2 delocalized electrons).
- aryl refers to an aromatic ring structure made up of from 5 to 14 carbon atoms. Ring structures containing 5, 6, 7 and 8 carbon atoms would be single-ring aromatic groups, for example, phenyl. Ring structures containing 8, 9, 10, 11, 12, 13, or 14 would be polycyclic, for example naphthyl.
- the aromatic ring can be substituted at one or more ring positions with such substituents as described above.
- aryl also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, for example, the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls.
- ortho, meta and para apply to 1,2-, 1,3- and 1 ,4-disubstituted benzenes, respectively.
- the names 1 ,2-dimethylbenzene and ortho-dimethylbenzene are synonymous.
- cycloalkyl is intended to include saturated ring groups, having the specified number of carbon atoms. These may include fused or bridged polycyclic systems. Preferred cycloalkyls have from 3 to 10 carbon atoms in their ring structure, and more preferably have 3, 4, 5, and 6 carbons in the ring structure.
- C 3- O cycloalkyl denotes such groups as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
- halo or “halogen” refers to fluoro, chloro, bromo, and iodo.
- Counterrion is used, for example, to represent a small, negatively charged species such as chloride, bromide, hydroxide, acetate, sulfate, tosylate, benezensulfonate, and the like.
- heterocyclyl or “heterocyclic” or “heterocycle” refers to a saturated, unsaturated or partially saturated, monocyclic, bicyclic or tricyclic ring (unless otherwise stated) containing 3 to 20 atoms of which 1, 2, 3, 4 or 5 ring atoms are chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH 2 - group is optionally be replaced by a -C(O)-; and where unless stated to the contrary a ring nitrogen or sulphur atom is optionally oxidised to form the N-oxide or S-oxide(s) or a ring nitrogen is optionally quarternized; wherein a ring -NH is optionally substituted by acetyl, formyl, methyl or mesyl; and a ring is optionally substituted by one or more halo.
- the heterocyclyl group is bi- or tricyclic then at least one of the rings may optionally be a he tero aromatic or aromatic ring provided that at least one of the rings is non-heteroaromatic. If the said heterocyclyl group is monocyclic then it must not be aromatic.
- heterocyclyls include, but are not limited to, piperidinyl, N- acetylpiperidinyl, 7V-methylpiperidinyl, 7V-formylpiperazinyl, 7V-mesylpiperazinyl, homopiperazinyl, piperazinyl, azetidinyl, oxetanyl, morpholinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolinyl, tetrahydropyranyl, dihydro-2H-pyranyl, tetrahydrofuranyl and 2,5-dioxoimidazolidinyl.
- heteroaryl refers to a heteroaromatic heterocycle having at least one heteroatom ring member such as sulfur, oxygen, or nitrogen.
- Heteroaryl groups include monocyclic and polycyclic (e.g., having 2, 3 or 4 fused rings) systems. Examples of heteroaryl groups include without limitation, pyridyl (i.e., pyridinyl), pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl (i.e.
- furanyl quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrryl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, benzothienyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, and the like.
- protecting group or “protective group” means temporary substituents which protect a potentially reactive functional group from undesired chemical transformations.
- protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively.
- a sub-group of protecting groups are those which protect a nucleophilic group (e.g. a phenolic hydroxy group or the N-H functionality of an indol-ring) against alkylation and thus permit selective 7V-alkylation of an amino-group present in the same molecule under basic conditions.
- examples of such protecting groups include, but is not limited to, methyl, 2-(trimethylsilyl)ethoxymethyl, alkoxymethyl and t-butyldimethylsilyl.
- pharmaceutically acceptable is employed to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
- pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof
- pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
- the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
- such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, phosphoric, and the like; and the salts prepared from organic acids such as lactic, maleic, citric, benzoic, methanesulfonic, and the like.
- the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods.
- such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are used.
- in vivo hydrolysable precursors means an in vivo hydrolysable (or cleavable) ester of a compound of the invention that contains a carboxy or a hydroxy group.
- amino acid esters C 1-6 alkoxymethyl esters like methoxymethyl; C 1- 6 alkanoyloxymethyl esters like pivaloyloxymethyl; C 3 -scycloalkoxycarbonyloxy esters like 1-cyclohexylcarbonyloxyethyl, acetoxymethoxy, or phosphoramidic cyclic esters.
- tautomer means other structural isomers that exist in equilibrium resulting from the migration of a hydrogen atom. For example, keto-enol tautomerism where the resulting compound has the properties of both a ketone and an unsaturated alcohol.
- stable compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and subsequent prolonged storage in the cold or at ambient temperature, and optionally formulated into an efficacious therapeutic or diagnostic agent.
- Compounds of the invention further include hydrates and solvates.
- the present invention includes isotopically labeled compounds of the invention.
- An "isotopically-labeled”, “radio-labeled”, “labeled”, “detectable” or “detectable amyloid binding” compound, or a “radioligand” is a compound of the invention where one or more atoms are replaced or substituted by an atom having an atomic mass or mass number different from the atomic mass or mass number typically found in nature (i.e., naturally occurring).
- One non-limiting exception is 19 F, which allows detection of a molecule which contains this element without enrichment to a higher degree than what is naturally occuring. Compounds carrying the substituent 19 F may thus also be referred to as "labeled” or the like.
- Suitable radionuclides that may be incorporated in compounds of the present invention include but are not limited to 2 H (also written as D for deuterium), 3 H (also written as T for tritium), 11 C, 13 C, 14 C, 13 N, 15 N, 15 O, 17 O, 18 O, 18 F, 35 S, 36 Cl, 82 Br, 75 Br, 76 Br, 77 Br, 123 1, 124 I, 125 I and 131 I. It is to be understood that an isotopically labeled compound of the invention need only to be enriched with a detectable isotop to, or above, the degree which allows detection with a technique suitable for the particular application, e.g.
- the carbon- atom of the labeled group of the labeled compound may be constituted by 12 C or other carbon-isotopes in a fraction of the molecules.
- the radionuclide that is incorporated in the instant radiolabeled compounds will depend on the specific application of that radiolabeled compound. For example, for in vitro plaque or receptor labeling and competition assays, compounds that incorporate 3 H, 14 C, or 125 I will generally be most useful. For in vivo imaging applications 11 C, 13 C, 18 F, 19 F, 120 1, 123 I, 131 I, 75 Br, or 76 Br will generally be most useful.
- an "effective amount” examples include amounts that enable imaging of amyloid deposit(s) in vivo, that yield acceptable toxicity and bioavailability levels for pharmaceutical use, and/or prevent cell degeneration and toxicity associated with fibril formation.
- This invention also provides radiolabeled 2-heteroaryl substituted indole derivatives as amyloid imaging agents agents and synthetic precursor compounds from which such are prepared.
- the compounds of the present invention may be used to determine the presence, location and/or amount of one or more amyloid deposit(s) in an organ or body area, including the brain, of an animal or human.
- Amyloid deposit(s) include, without limitation, deposit(s) of A ⁇ .
- the inventive compounds may farther be used to correlate amyloid deposition with the onset of clinical symptoms associated with a disease, disorder or condition.
- the inventive compounds may ultimately be used to treat, and to diagnose a disease, disorder or condition characterized by amyloid deposition, such as AD, familial AD, Down's syndrome, amyloidosis and homozygotes for the apolipoprotein E4 allele.
- the method of this invention determines the presence and location of amyloid deposits in an organ or body area, preferably brain, of a patient.
- the present method comprises administration of a detectable quantity of a pharmaceutical composition containing an amyloid-binding compound of the present invention called a "detectable compound," or a pharmaceutically acceptable water-soluble salt thereof, to a patient.
- a “detectable quantity” means that the amount of the detectable compound that is administered is sufficient to enable detection of binding of the compound to amyloid.
- An “imaging effective quantity” means that the amount of the detectable compound that is administered is sufficient to enable imaging of binding of the compound to amyloid.
- the invention employs amyloid probes which, in conjunction with non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MINI), or gamma imaging such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT), are used to quantify amyloid deposition in vivo.
- non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MINI), or gamma imaging such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)
- imaging refers to any method which permits the detection of a labeled heteroaryl substituted indole derivative as described herein.
- the radiation emitted from the organ or area being examined is measured and expressed either as total binding or as a ratio in which total binding in one tissue is normalized to (for example, divided by) the total binding in another tissue of the same subject during the same in vivo imaging procedure.
- Total binding in vivo is defined as the entire signal detected in a tissue by an in vivo imaging technique without the need for correction by a second injection of an identical quantity of labeled compound along with a large excess of unlabeled, but otherwise chemically identical compound.
- a "subject” is a mammal, preferably a human, and most preferably a human suspected of having dementia.
- the type of detection instrument available is a major factor in selecting a given label.
- radioactive isotopes and 19 F are particularly suitable for in vivo imaging in the methods of the present invention.
- the type of instrument used will guide the selection of the radionuclide or stable isotope.
- the radionuclide chosen must have a type of decay detectable by a given type of instrument.
- Another consideration relates to the half-life of the radionuclide. The half-life should be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that the host does not sustain deleterious radiation.
- the radiolabeled compounds of the invention can be detected using gamma imaging wherein emitted gamma irradiation of the appropriate wavelength is detected.
- Methods of gamma imaging include, but are not limited to, SPECT and PET.
- the chosen radiolabel will lack a particulate emission, but will produce a large number of photons in a 140-200 keV range.
- the radiolabel will be a positron-emitting radionuclide, such as 18 F or 11 C, which will annihilate to form two gamma rays which will be detected by the PET camera.
- amyloid binding compounds/probes are made which are useful for in vivo imaging and quantification of amyloid deposition. These compounds are to be used in conjunction with non-invasive neuroimaging techniques such as magnetic resonance spectroscopy (MRS) or imaging (MRI), positron emission tomography (PET), and single- photon emission computed tomography (SPECT).
- MRS magnetic resonance spectroscopy
- PET positron emission tomography
- SPECT single- photon emission computed tomography
- the 2- heteroaryl substituted indole derivatives may be labeled with 19 F or 13 C for MRS/MRI by general organic chemistry techniques known in the art.
- the compounds may also be radiolabeled with, for example, 18 F, 11 C, 75 Br, 76 Br, or 120 I for PET by techniques well known in the art and are described by Fowler, J.
- the compounds also may be radiolabeled with 123 I and 131 I for SPECT by any of several techniques known to the art. See, e.g., Kulkarni, Int. J. Rad. Appl. &Inst. (Part B) 18: 647 (1991).
- the compounds may also be radiolabeled with known metal radiolabels, such as Technetium- 99m ( 99m Tc). Modification of the substituents to introduce ligands that bind such metal ions can be effected without undue experimentation by one of ordinary skill in the radiolabeling art.
- the metal radiolabeled compound can then be used to detect amyloid deposits.
- Preparing radiolabeled derivatives of Tc-99m is well known in the art. See, for example, Zhuang et al. Nuclear Medicine & Biology 26(2):217-24, (1999); Oya et al. Nuclear Medicine &Biology 25(2) : 135-40, (1998), and Horn et al. Nuclear Medicine &Biology 24(6):485-98, (1997).
- the compounds may be labeled with 3 H, 14 C and 125 I, by methods well known to the one skilled in the art, for detection of amyloid plaque in in vitro and post mortem samples.
- fluorescent compounds of the present invention may be used for the detection of plaques present in in vitro and post mortem samples by employment of well known techniques based on the detection of fluorescence.
- the methods of the present invention may use isotopes detectable by nuclear magnetic resonance spectroscopy for purposes of in vivo imaging and spectroscopy.
- Elements particularly useful in magnetic resonance spectroscopy include 19 F and 13 C.
- Suitable radioisotopes for purposes of this invention include beta-emitters, gamma- emitters, positron-emitters, and x-ray emitters. These radioisotopes include 120 I, 123 1, 131 I,
- Imaging or Spectroscopy (MRS), according to this invention, include 19 F and 13 C.
- Suitable radioisotopes for in vitro quantification of amyloid in homogenates of biopsy or post-mortem tissue include 125 I, 14 C, and 3 H.
- the preferred radiolabels are 11 C and 18 F for use in PET in vivo imaging, 123 I for use in SPECT imaging, 19 F for MRS/MRI, and 3 H and
- the compounds of the present invention may be administered by any means known to one of ordinary skill in the art.
- administration to the animal may be local or systemic and accomplished orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally, or via an implanted reservoir.
- parenteral as used herein includes subcutaneous, intravenous, intraarterial, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal, intracranial, and intraosseous injection and infusion techniques.
- Dose levels on the order of about 0.001 ⁇ g/kg/day to about 10,000 mg/kg/day of an inventive compound are useful for the inventive methods.
- the dose level is about 0.001 ⁇ g/kg/day to about 10 g/kg/day.
- the dose level is about 0.01 ⁇ g/kg/day to about 1.0 g/kg/day.
- the dose level is about 0.1 mg/kg/day to about 100 mg/kg/day.
- the specific dose level for any particular patient will vary depending upon various factors, including the activity and the possible toxicity of the specific compound employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the rate of excretion; the drug combination; and the form of administration.
- in vitro dosage-effect results provide useful guidance on the proper doses for patient administration. Studies in animal models are also helpful. The considerations for determining the proper dose levels are well known in the art and within the skills of an ordinary physician.
- Any known administration regimen for regulating the timing and sequence of drug delivery may be used and repeated as necessary to effect treatment in the inventive methods.
- the regimen may include pretreatment and/or co-administration with additional therapeutic agent(s).
- the inventive compounds are administered to an animal that is suspected of having or that is at risk of developing a disease, disorder or condition characterized by amyloid deposition.
- the animal may be an elderly human.
- compounds and methods for their preparation useful as precursors, are provided.
- Such precursors may be used as synthetic starting materials for the incorporation of labeled molecular fragments leading to radiolabeled 2-heteroaryl substituted indole derivatives as amyloid imaging agents.
- This invention further provides a method for detecting amyloid deposit(s) in vitro comprising: (i) contacting a bodily tissue with an effective amount of an inventive compound, wherein the compound would bind any amyloid deposit(s) in the tissue; and (ii) detecting binding of the compound to amyloid deposit(s) in the tissue.
- the binding may be detected by any means known in the art. Examples of detection means include, without limitation, microscopic techniques, such as bright-field, fluorescence, laser-confocal and cross-polarization microscopy.
- This invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising: (i) an effective amount of at least one inventive compound; and (ii) a pharmaceutically acceptable carrier.
- composition may comprise one or more additional pharmaceutically acceptable ingredient(s), including without limitation one or more wetting agent(s), buffering agent(s), suspending agent(s), lubricating agent(s), emulsifier(s), disintegrant(s), absorbent(s), preservative(s), surfactant(s), colorant(s), flavorant(s), sweetener(s) and therapeutic agent(s).
- additional pharmaceutically acceptable ingredient(s) including without limitation one or more wetting agent(s), buffering agent(s), suspending agent(s), lubricating agent(s), emulsifier(s), disintegrant(s), absorbent(s), preservative(s), surfactant(s), colorant(s), flavorant(s), sweetener(s) and therapeutic agent(s).
- the composition may be formulated into solid, liquid, gel or suspension form for: (1) oral administration as, for example, a drench (aqueous or non-aqueous solution or suspension), tablet (for example, targeted for buccal, sublingual or systemic absorption), bolus, powder, granule, paste for application to the tongue, hard gelatin capsule, soft gelatin capsule, mouth spray, emulsion and microemulsion; (2) parenteral administration by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution, suspension or sustained-release formulation; (3) topical application as, for example, a cream, ointment, controlled- release patch or spray applied to the skin; (4) intravaginal or intrarectal administration as, for example, a pessary, cream or foam; (5) sublingual administration; (6) ocular administration; (7) transdermal administration; or (8) nasal administration.
- oral administration as, for example, a drench (aqueous or non-aqueous solution or
- the composition is formulated for intravenous administration and the carrier includes a fluid and/or a nutrient replenisher.
- the composition is capable of binding specifically to amyloid in vivo, is capable of crossing the blood-brain barrier, is non-toxic at appropriate dose levels and/or has a satisfactory duration of effect.
- the composition comprises about 10 mg of human serum albumin and from about 0.0005 to 500 mg of a compound of the present invention per mL of phosphate buffer containing NaCl.
- compositions comprising a compound of formula Ia, and and at least one pharmaceutically acceptable carrier, diluent or excipient.
- the present invention further provides methods of treating or preventing an A ⁇ -related pathology in a patient, comprising administering to the patient a therapeutically effective amount of a compound of formula Ia
- the present invention further provides a compound described herein for use as a medicament.
- the present invention further provides a compound described herein for the manufacture of a medicament.
- Some compounds of formula Ia and Ib may have stereogenic centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention encompasses all such optical isomers, enantiomers, diastereoisomers, atropisomers and geometric isomers.
- the present invention relates to the use of compounds of formula Ia as hereinbefore defined as well as to the salts thereof.
- Salts for use in pharmaceutical compositions will be pharmaceutically acceptable salts, but other salts may be useful in the production of the compounds of formula Ia.
- the present invention provides compounds of formula Ia, or pharmaceutically acceptable salts, tautomers or in vzv ⁇ -hydrolysable precursors thereof, for use as medicaments.
- the present invention provides compounds described here in for use as as medicaments for treating or preventing an A ⁇ -related pathology.
- the A ⁇ -related pathology is Downs syndrome, a ⁇ -amyloid angiopathy, cerebral amyloid angiopathy, hereditary cerebral hemorrhage, a disorder associated with cognitive impairment, MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with Alzheimer disease, dementia of mixed vascular origin, dementia of degenerative origin, pre-senile dementia, senile dementia, dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
- MCI mimild cognitive impairment
- the present invention also relates to processes for preparing the compound of formula Ia and Ib as a free base, acid, or salts thereof.
- suitable protecting groups will be attached to, and subsequently removed from, the various reactants and intermediates in a manner that will be readily understood by one skilled in the art of organic synthesis.
- Conventional procedures for using such protecting groups, as well as examples of suitable protecting groups, are described, for example, in "Protective Groups in Organic
- Halogenation at the 2-position of indoles can be achieved by TV-protection of the indole, with for example BoC 2 O, followed by treatment with BuLi and I 2 to afford the 2-iodo- indole (Roy et al. Tetrahedron Lett. 2005, 46, 1325-1328).
- b) By Katritzkys method of using BuLi and then CO 2 as an activating and TV-protecting group Karlitzky et al. Tetrahedron Lett.
- a palladium catalyst such as Pd(dppf)Cl 2 may be used in a solvent such as DMF or THF at a temperature of e.g. 80 0 C. (Kotha et al.
- Reagents labeled with relatively more short-lived isotopes are generated by a cyclotron, followed by suitable trapping and optionally further synthetic manipulations to provide the desired reagent.
- the generation and the synthetic manipulations of labeled reagents and intermediates, and the use and chemistries of these precursors for the synthesis of more complex labeled molecules is well known to the one skilled in the art of radio-synthesis and labeling and is reviewed in the literature (Langstrom et al. Acta Chem. Scand. 1999, 53, 651). For additional references see for example: AIi et al.
- Detectable isotopes useful for the labeling of compounds of formula Ia as defined herein include, for use in PET: 11 C, 18 F, 75 Br, 76 Br and 120 I, for use in SPECT: 123 I and 131 I, for MRI-applications: 19 F and 13 C, for detection in in-vitro and post-mortem samples: 3 H, 14 C and 125 I.
- the most useful isotopes for labeling are 11 C, 18 F, 123 1, 19 F, 3 H and 14 C.
- the compounds of formula Ia in which one of Rl and R2 is hydroxy (the other is hydrogen), or compounds of formula Ib, in which one of R8 and Rl 1 is hydroxy (the other is hydrogen), or constitute precursors for labeling.
- a precursor is treated with [ ⁇ C]methyl iodide under basic condition, such as in the presence of potassium carbonate, in a solvent such as DMSO, selective O-alkylation occurs in the presence of N- nucleophiles, such as amino, aminomethyl or the indole N-H functionality, because of relatively higher reactivity of the oxygen-atom after deprotonation, and thus in the formation of compounds of formula Ia and Ib in which the OH-group has been transformed into the O[ ⁇ C]CH3-group.
- the most preferred precursors for labeling by selective introduction of a n C-methyl group by /V-alkylation are compounds in which the reactivity to alkylation, of a present competing nucleophilic functional group, such as hydroxy or the indole N-H functionality, is lowered or blocked by a suitable protective group.
- the function of the protective group is, in this context, to protect the nucleophilic functional group from alkylation and should preferrably be stable under non-aqueous basic conditions, under which the desired N- alkylation is facilitated, but readily removed by other means after fulfilment of its duty.
- Such protective groups, and methods for their introduction and removal are well known to the one skilled in the art.
- protective groups useful for protection of aromatic hydroxy-groups against competing alkylation include, but is not limited to, methyl, 2- (trimethylsilyl)ethoxymethyl, alkoxymethyl and t-butyldimethylsilyl. Removal of such a protective group after the alkylation is well known to the one skilled in the art and include, in the case of silyl-based protective groups such as t-butyldimethylsilyl, for example treatment with a fluoride ion source, such as TBAF, or treatment with water under basic conditions in a suitable solvent, such as DMSO in the presence of KOH at rt.
- a fluoride ion source such as TBAF
- DMSO suitable solvent
- one protective group such as t-butyldimethylsilyl
- two different protective groups which allow simultaneous de -protection of both functionalities in one laboratory step by employment of one de-protection reagent.
- Compounds of formula Ia or Ib, carrying an aromatic amino-group are useful precursor for labeling by initial diazotation (i.e. transformation of the amino-group into the N 2 + moiety), when appropriate, followed by conversion into the corresponding triazine derivative before subsequent treatment with labeled nucleophilic reagents according to standard reactions.
- Detectable isotopes that may be introduced this way include, but is not limited to 18 F, 75 Br, 123 I, 125 I and 131 I as described in for example Zhu et al. J. Org. Chem. 2002, 67, 943; Maeda et al. J. Label Compd Radiopharm 1985, 22, 487; Berridge et al. J.
- the same precursors are also useful for palladium-catalyzed conversion into the corresponding ⁇ C-labeled ketones and methyl-derivatives as described in for example Lidstrom et al. J. Chem. Soc. Perkin Trans. 1 1997, 2701 and Tarkiainen et al. J. Label Compd Radiopharm 2001, 44, 1013.
- the trialkyltin substituted compounds are preferably prepared from the corresponding halides or pseudo-halides, such as the trifiates, by well known methods employing palladium as catalyst in reaction with the corresponding distannane. When this methodology is used, the trialkyltin-group is preferably trimethyltin or tributyltin.
- X6 is carbon
- X7 or X8 is nitrogen (the other is carbon)
- RlO is methylamino, dimethylamino or methoxy
- a labeled nucleophile such as a halogenide or cyanide
- a labeled compound of formula Ia can be introduced by such a displacement resulting in a labeled compound of formula Ia, as described in for example Zhang et al. Appl. Rad. Isot. 2002, 57, 145.
- the aromatic ring on which the displacement takes place is preferably relatively electron-poor for a facile reaction, and might therefore need to be substituted with an electron-withdrawing activating group such as cyano, carbaldehyde or nitro.
- Useful reactions include the employment of stochiometric amounts of copper-salts for the introduction of a labeled iodo-atom, and the use of palladium-catalysis for the introduction of a ⁇ C-labelled cyano- group, as described in for example Musacio et al. J. Label Compd Radiopharm 1997, 34, 39 and Andersson et al. J. Label Compd Radiopharm 1998, 41, 567 respectively.
- an 18 F-atom may be introduced, for example by use OfK[ 18 F]-K 222 in DMSO under microwave irradiation as described in Karramkam, M. et al. J.
- Other suitable leaving groups that may be employed are well known to the one skilled in the art and include, but is not limited to bromo, iodo, OSO 2 CF 3 , OSO 2 CH 3 and 0S0 2 phenyl.
- 3 H spectra were recorded on a Bruker DRX600 NMR Spectrometer, operating at 640 MHz for tritium and at 600 MHz for proton, equipped with a 5mm 3 HZ 1 H SEX probehead with Z-gradients. 1 H decoupled 3 H spectra were recorded on samples dissolved in CD3OD.
- a ghost reference frequency was used, as calculated by multiplying the frequency of internal TMS in a 1 H spectrum with the Larmor frequency ratio between 3 H and 1 H (1.06663975), according to the description in Al-Rawi et al. J. Chem. Soc. Perkin Trans. II 1974, 1635.
- Mass spectra were recorded on a Waters LCMS consisting of an Alliance 2795 or Acquity system (LC), Waters PDA 2996, and ELS detector (Sedex 75) and a ZMD single quadrupole or ZQ mass spectrometer.
- the mass spectrometer was equipped with an electrospray ion source (ES) operated in a positive or negative ion mode.
- the capillary voltage was 3 kV and cone voltage was 30 V.
- the mass spectrometer was scanned between m/z 100-600 with a scan time of 0.7 s.
- the column temperature was set to 40 0 C (Alliance) or 65 0 C (Acquity).
- Microwave heating was performed in a Creator, Initiator or Smith Synthesizer Single- mode microwave cavity producing continuous irradiation at 2450 MHz.
- Dissociation experiments were performed in 96-well polypropylene deep well plates. 2 ⁇ M human synthetic A ⁇ 1-40 fibrils in phosphate buffer pH 7.5, or buffer alone as control, was incubated with 9 nM of a 3 H-labeled radioligand of the present invention for 4 h at room temperature. Dissociation was started at different time points, by the addition of an equal volume of a non-labeled compound of the present invention, or a reference compound (10 ⁇ M), in 4 % DMSO in phosphate buffer at pH 7.5. The radioactivity still bound to the A ⁇ 1-40 fibrils at the end of the incubation was detected on FB filters after filtration in a Brandel apparatus using a wash buffer containing 0.1 % Triton-XIOO.
- Brain exposure after i.v administration was determined in rat brains using cassette dosing. Four different compounds were dosed followed by plasma and brain sampling at 2 and 30 minutes after the dosing. 2 to 30 min brain concentration ratios, and percentage of total of injected dose after 2 mins found in brain, were calculated. The compound concentrations were determined by analysis of protein precipitated plasma samples by reversed-phase liquid chromatography coupled to a electrospray tandem mass spectrometer.
- Sections were preincubated for 30 minutes at room temperature in 50 mM Tris HCl (pH 7.4) in the presence or absence of 1 ⁇ M PIB. Sections were transferred to buffer containing tritium-labeled compound (1 nM) with or without PIB (1 ⁇ M) and incubated for 30 minutes at room temperature. Incubation was terminated by 3 consecutive 10 minute rinses in buffer (I 0 C) followed by a rapid rinse in distilled water (I 0 C). Sections were air dried in front of a fan. Dried sections and plastic tritium standards (Amersham microscales- 3 H) were apposed to phospho image plates (Fuji) in a cassette and exposed overnight.
- mice Binding in APP/PS1 mouse brain after compound administration in- vivo Naive, awake mice were restrained and intravenously infused via the tail vein with either a tritium labeled compound of the present invention, or a tritium labeled reference compound via the tail vein.
- the animals were rapidly anesthetized with isofluorane and decapitated twenty minutes after compound administration (1 mCi).
- mice were given 1 mCi of a compound and were anesthetized and decapitated at a timepoint of 20, 40 or 80 minutes after administration. Brains were removed and frozen with powdered dry ice. Brains were sectioned (10 ⁇ m) in the coronal plane at the level of the striatum with a cryostat, thaw- mounted onto superfrost microscope slides and air-dried.
- NAME IC50 methyl 6-(5-hydroxy-1 H-indol-2- yl)nicotinate methyl 6-(5-methoxy-1 H-indol-2- yl)nicotinate
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2008221667A AU2008221667A1 (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indoles 695 |
US12/529,850 US20100098631A1 (en) | 2007-03-06 | 2008-03-05 | Novel-2-Heteroaryl Substituted Indoles 695 |
JP2009552640A JP2010520275A (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indole 695 |
EP08724189A EP2121655A4 (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indoles 695 |
MX2009009113A MX2009009113A (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indoles 695. |
BRPI0808090-9A2A BRPI0808090A2 (en) | 2007-03-06 | 2008-03-05 | COMPOUND, PHARMACEUTICAL COMPOSITION, AND IN VIVO METHOD FOR MEASURING AMYLOID DEPOSITS IN A PATIENT |
CA002680055A CA2680055A1 (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indoles 695 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89315107P | 2007-03-06 | 2007-03-06 | |
US60/893,151 | 2007-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008108729A1 true WO2008108729A1 (en) | 2008-09-12 |
Family
ID=39738509
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2008/050242 WO2008108729A1 (en) | 2007-03-06 | 2008-03-05 | Novel 2-heteroaryl substituted indoles 695 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20100098631A1 (en) |
EP (1) | EP2121655A4 (en) |
JP (1) | JP2010520275A (en) |
KR (1) | KR20090115954A (en) |
CN (1) | CN101636395A (en) |
AU (1) | AU2008221667A1 (en) |
BR (1) | BRPI0808090A2 (en) |
CA (1) | CA2680055A1 (en) |
MX (1) | MX2009009113A (en) |
RU (1) | RU2009133256A (en) |
WO (1) | WO2008108729A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
US8030334B2 (en) | 2008-06-27 | 2011-10-04 | Novartis Ag | Organic compounds |
CN102227431A (en) * | 2008-09-29 | 2011-10-26 | 雅培制药有限公司 | Indole and indoline derivatives and methods of use thereof |
US8530483B2 (en) | 2008-05-30 | 2013-09-10 | Merck Sharp & Dohme Corp. | Substituted azabenzoxazoles |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114380731A (en) * | 2022-03-09 | 2022-04-22 | 台州学院 | KCNQ potassium channel agonist, pharmaceutical composition and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006125324A1 (en) * | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4317955B2 (en) * | 2001-04-23 | 2009-08-19 | ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Amyloid plaque aggregation inhibitor and diagnostic contrast agent |
CA2438032C (en) * | 2003-03-14 | 2013-05-07 | University Of Pittsburgh | Benzothiazole derivative compounds, compositions and uses |
-
2008
- 2008-03-05 US US12/529,850 patent/US20100098631A1/en not_active Abandoned
- 2008-03-05 CA CA002680055A patent/CA2680055A1/en not_active Abandoned
- 2008-03-05 CN CN200880007424A patent/CN101636395A/en active Pending
- 2008-03-05 WO PCT/SE2008/050242 patent/WO2008108729A1/en active Application Filing
- 2008-03-05 JP JP2009552640A patent/JP2010520275A/en active Pending
- 2008-03-05 BR BRPI0808090-9A2A patent/BRPI0808090A2/en not_active IP Right Cessation
- 2008-03-05 KR KR1020097018582A patent/KR20090115954A/en not_active Application Discontinuation
- 2008-03-05 EP EP08724189A patent/EP2121655A4/en not_active Withdrawn
- 2008-03-05 AU AU2008221667A patent/AU2008221667A1/en not_active Abandoned
- 2008-03-05 MX MX2009009113A patent/MX2009009113A/en not_active Application Discontinuation
- 2008-03-05 RU RU2009133256/04A patent/RU2009133256A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006125324A1 (en) * | 2005-05-27 | 2006-11-30 | Queen's University At Kingston | Treatment of protein folding disorders |
Non-Patent Citations (3)
Title |
---|
DATABASE HCAPLUS [online] BENHIDA R. ET AL.: "Synthesis of 6-allyl- and 6-heteroarylindoles by palladium catalyzed stille cross-coupling reaction", XP008112551, accession no. STN Database accession no. (1999:476741) * |
See also references of EP2121655A4 * |
TETRAHEDRON LETTERS, vol. 40, no. 31, 1999, pages 5701 - 5703 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8530483B2 (en) | 2008-05-30 | 2013-09-10 | Merck Sharp & Dohme Corp. | Substituted azabenzoxazoles |
US8030334B2 (en) | 2008-06-27 | 2011-10-04 | Novartis Ag | Organic compounds |
US8791141B2 (en) | 2008-06-27 | 2014-07-29 | Novartis Ag | Organic compounds |
US9242963B2 (en) | 2008-06-27 | 2016-01-26 | Novartis Ag | Organic compounds |
CN102227431A (en) * | 2008-09-29 | 2011-10-26 | 雅培制药有限公司 | Indole and indoline derivatives and methods of use thereof |
WO2011045415A2 (en) | 2009-10-15 | 2011-04-21 | Guerbet | New imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases |
Also Published As
Publication number | Publication date |
---|---|
MX2009009113A (en) | 2009-09-04 |
CA2680055A1 (en) | 2008-09-12 |
RU2009133256A (en) | 2011-04-20 |
JP2010520275A (en) | 2010-06-10 |
AU2008221667A1 (en) | 2008-09-12 |
KR20090115954A (en) | 2009-11-10 |
US20100098631A1 (en) | 2010-04-22 |
CN101636395A (en) | 2010-01-27 |
EP2121655A4 (en) | 2010-09-22 |
EP2121655A1 (en) | 2009-11-25 |
BRPI0808090A2 (en) | 2014-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8957215B2 (en) | Heteroaryl substituted benzothiazoles | |
US7670591B2 (en) | Heteroaryl substituted benzoxazoles | |
EP2132201B1 (en) | Novel 2-heteroaryl substituted benzothiophenes and benzofuranes | |
US20100092385A1 (en) | Novel Heteroaryl Substituted Imidazo [1,2-A] Pyridine Derivatives | |
US20100098631A1 (en) | Novel-2-Heteroaryl Substituted Indoles 695 | |
RU2472789C2 (en) | Novel 2-heteroaryl-substituted benzothiophenes and benzofurans 709 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880007424.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08724189 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008221667 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5403/DELNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/009113 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12529850 Country of ref document: US Ref document number: 2680055 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009552640 Country of ref document: JP Ref document number: 1020097018582 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2008221667 Country of ref document: AU Date of ref document: 20080305 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008724189 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009133256 Country of ref document: RU |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0808090 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0808090 Country of ref document: BR Kind code of ref document: A2 Effective date: 20090827 |